EGFR and glioblastoma: Furthermore, a recent phase III clinical trial evaluated the efficacy of the combination treatment of temozolomide and the antibody-drug conjugate depatuxizumab mafodotin (ABT-414)—an EGFR antibody linked to monomethyl auristatin F—in newly diagnosed GBM [79].